Advanced Wound Care And Health Information Systems Will Transform Long Term Earnings Power

Catalysts

About Solventum

Solventum is a global health care company focused on MedSurg, Dental Solutions and Health Information Systems for providers worldwide.

What are the underlying business or industry changes driving this perspective?

• Ramp up in Advanced Wound Care therapies such as single use Prevena and V.A.C Peel and Place Dressings, supported by strong clinical differentiation and underpenetration, can support volume driven revenue growth and operating margin expansion as higher value therapies scale.
• Expansion of Tegaderm antimicrobial IV site management solutions across Europe, Asia and the US, with customers trading up from standard films, can lift mix toward premium products and support higher net margins through better pricing and utilization of the existing commercial channel.
• Growth in AI driven Health Information Systems, including autonomous coding and 360 Encompass installations in markets such as Australia and the Middle East, can increase recurring software and services revenue and support earnings through higher margin digital offerings.
• The Transform for the Future program, targeting approximately US$500 million of annual savings over four years through ERP ownership, automation, supply chain simplification and cost management, can support operating margin improvement and contribute to EPS growth even with tariff headwinds.
• Portfolio optimization, including SKU rationalization, the sale of the Purification & Filtration business and a focus on tuck in M&A in existing markets, can concentrate capital and commercial resources on higher growth and higher margin categories, supporting revenue quality and free cash flow.

Assumptions

This narrative explores a more optimistic perspective on Solventum compared to the consensus, based on a Fair Value that aligns with the bullish cohort of analysts. How have these above catalysts been quantified?

• The bullish analysts are assuming Solventum's revenue will grow by 1.2% annually over the next 3 years.
• The bullish analysts assume that profit margins will increase from 18.1% today to 37.0% in 3 years time.
• The bullish analysts expect earnings to reach $3.2 billion (and earnings per share of $3.04) by about January 2029, up from $1.5 billion today. The analysts are largely in agreement about this estimate.
• In order for the above numbers to justify the price target of the more bullish analyst cohort, the company would need to trade at a PE ratio of 7.3x on those 2029 earnings, down from 9.6x today. This future PE is lower than the current PE for the US Medical Equipment industry at 30.8x.
• The bullish analysts expect the number of shares outstanding to grow by 0.26% per year for the next 3 years.
• To value all of this in today's terms, we will use a discount rate of 8.49%, as per the Simply Wall St company report.

Risks

What could happen that would invalidate this narrative?

• Long-running tariff pressures are already having a 130 basis point impact on gross margin in the quarter and management expects a greater headwind in Q4 and into 2026. If mitigation and the Transform for the Future savings program do not offset these pressures, the result could be lower gross margins and slower operating margin expansion than implied in the bullish view, which would weigh on earnings.
• The separation from 3M and multi year ERP and supply chain changes still underway, including further manufacturing line transitions and remaining system cutovers planned into 2026, carry ongoing execution and disruption risk. Any sustained issues with order fulfillment, service levels or additional separation costs could pressure revenue growth and limit near term margin progress.
• The portfolio optimization plan depends on continuous SKU rationalization and successful tuck in M&A under US$1b in areas where Solventum already operates. If acquisition opportunities do not meet expectations or integrations are more expensive or slower than planned, the company may not see the expected lift in revenue quality, while deal and restructuring costs could drag on net margins and free cash flow.
• Growth in Health Information Systems is partly tied to revenue cycle consulting fees, service milestones and large 360 Encompass and autonomous coding installations. If hospitals slow spending on these offerings or competitor solutions gain share over time, that could reduce higher margin software and services contribution and limit earnings growth.
• The long term plan assumes sustained premium growth drivers in Advanced Wound Care, Infection Prevention, Dental and Tegaderm antimicrobial solutions, yet these depend on continued product uptake, conversion from standard films and favorable reimbursement. Any change in clinician behavior, payer policies or competitive offerings could slow volume growth and mix improvement, leading to lower revenue and more modest net margin expansion than the bullish scenario implies.

Valuation

How have all the factors above been brought together to estimate a fair value?

• The assumed bullish price target for Solventum is $105.0, which represents up to two standard deviations above the consensus price target of $87.18. This valuation is based on what can be assumed as the expectations of Solventum's future earnings growth, profit margins and other risk factors from analysts on the bullish end of the spectrum.
  
• However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $105.0, and the most bearish reporting a price target of just $71.0.
  
• In order for you to agree with the more bullish analyst cohort, you'd need to believe that by 2029, revenues will be $8.7 billion, earnings will come to $3.2 billion, and it would be trading on a PE ratio of 7.3x, assuming you use a discount rate of 8.5%.
  
• Given the current share price of $84.24, the analyst price target of $105.0 is 19.8% higher.
  
• We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.